Literature DB >> 4418481

Effect of cholinergic and anticholinergic agents on tardive dyskinesia.

H L Klawans, R Rubovits.   

Abstract

Tardive dyskinesia, like several other choreiform disorders, is felt to be primarily related to dopaminergic activity within the striatum. Physostigmine has been demonstrated to improve the abnormal movements in patients with tardive dyskinesia while scopolamine tends to aggravate abnormal movements and in some cases elicits abnormal movement not previously observed. This evidence supports the hypothesis that anticholinergic therapy in patients prone to develop tardive dyskinesia may increase the incidence of this disorder by lowering the threshold for the appearance of these movements.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4418481      PMCID： PMC494809          DOI： 10.1136/jnnp.37.8.941

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

Review 1.  Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors:  H Klawans; M M Ilahi; D Shenker
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

Review 2.  The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases.

Authors:  A Faurbye
Journal:  Compr Psychiatry       Date:  1970-05       Impact factor: 3.735

3.  [Alpha- methyl-P-tyrosine effect in extrapyramidal diseases].

Authors:  W Birkmayer
Journal:  Wien Klin Wochenschr       Date:  1969-01-03       Impact factor: 1.704

4.  Cholinergic-anticholinergic antagonism in parkinsonism.

Authors:  R C Duvoisin
Journal:  Arch Neurol       Date:  1967-08

Review 5.  The pharmacology of parkinsonism (a review).

Authors:  H L Klawans
Journal:  Dis Nerv Syst       Date:  1968-12

6.  A pharmacologic analysis of Huntington's chorea.

Authors:  H L Klawans
Journal:  Eur Neurol       Date:  1970       Impact factor: 1.710

7.  Central cholinergic-anticholinergic antagonism in Huntington's chorea.

Authors:  H L Klawans; R Rubovits
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

8.  Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia.

Authors:  H L Klawans; R R McKendall
Journal:  J Neurol Sci       Date:  1971-10       Impact factor: 3.181

9.  "Permanent" or complex dyskinesias in the aged.

Authors:  G W Paulson
Journal:  Geriatrics       Date:  1968-09

10.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245
View more
  32 in total

1.  Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.

Authors:  J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 3.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

4.  Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug.

Authors:  G Chouinard; D Boisvert; J Bradwejn
Journal:  Can Med Assoc J       Date:  1982-04-01       Impact factor: 8.262

5.  Problems in monitoring needs for care of long term psychiatric patients: evaluating a service for casual attenders.

Authors:  S Compton; T Brugha
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1988-04       Impact factor: 4.328

6.  Medications influencing central cholinergic pathways affect fixation stability, saccadic response time and associated eye movement dynamics during a temporally-cued visual reaction time task.

Authors:  Preshanta Naicker; Shailendra Anoopkumar-Dukie; Gary D Grant; Luca Modenese; Justin J Kavanagh
Journal:  Psychopharmacology (Berl)       Date:  2016-12-17       Impact factor: 4.530

Review 7.  Management of tardive dyskinesia: current update.

Authors:  G M Simpson; E H Pi; J J Sramek
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

8.  Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.

Authors:  Julie Eve Desmarais; Linda Beauclair; Lawrence Annable; Marie-Claire Bélanger; Theodore T Kolivakis; Howard C Margolese
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

9.  Oral dyskinesia in rats following brain lesions and neuroleptic drug administration.

Authors:  L M Gunne; J Growdon; B Glaeser
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Authors:  Tanuja Bordia; Danhui Zhang; Xiomara A Perez; Maryka Quik
Journal:  Exp Neurol       Date:  2016-09-19       Impact factor: 5.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.